Simulations Plus (SLP) Projected to Post Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is expected to be posting its quarterly earnings results after the market closes on Thursday, April 3rd. Analysts expect Simulations Plus to post earnings of $0.25 per share and revenue of $21.93 million for the quarter.

Simulations Plus Trading Down 1.7 %

Shares of Simulations Plus stock opened at $24.10 on Wednesday. The business’s fifty day moving average price is $30.54 and its 200 day moving average price is $30.42. Simulations Plus has a twelve month low of $23.44 and a twelve month high of $51.22. The stock has a market capitalization of $484.22 million, a P/E ratio of 60.25 and a beta of 0.89.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now owns 3,402,584 shares in the company, valued at $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 19.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.